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ABSTRACT: Albumin transports both fatty acids and
zinc in plasma. Competitive binding studied by isothermal
titration calorimetry revealed that physiologically relevant
levels of fatty acids modulate the Zn-binding capacity of
albumin, with far-reaching implications for biological zinc
speciation. The molecular mechanism for this effect is
likely due to a large conformational change elicited by fatty
acid binding to a high-affinity interdomain site that
disrupts at least one Zn site. Albumin may be a molecular
device to “translate” certain aspects of the organismal
energy state into global zinc signals.
W
e present evidence for a fatty-acid-mediated reduction in
the Zn-binding ability of serum albumin. This provides a
direct molecular link between fatty acid metabolism and the
plasma Zn distribution.
A plethora of biological pathways and signaling cascades are
directly affected by zinc,
1 and many disease states, including
neurodegenerative and cardiovascular diseases, diabetes melli-
tus, asthma, and cancer, are accompanied by systemic zinc
dyshomeostasis.
2,3 However, in the majority of cases, the
underlying molecular mechanisms remain unknown. One
important area of interest concerns the links between zinc
homeostasis and energy metabolism.
4 Besides the well-
established link between zinc and insulin,
5 extensive phenom-
enological data at the organismal and cellular levels are available
for other pathways influenced by zinc; for example, it is well-
known that zinc affects appetite
6 and that the synthesis of fatty
acids and their esterification in adipocytes (lipogenesis) is zinc-
induced.
7 Thus, zinc clearly has a multifaceted regulatory/
signaling role in fat metabolism.
Understanding the regulatory roles of zinc in a biological
system requires an understanding of Zn-trafficking mechanisms.
How does the appropriate amount of Zn reach the appropriate
cells in a healthy individual? How does Zn dyshomeostasis
occur, and how does this affect metabolic processes? Much
recent progress has been made with the identification and study
of the many membrane-bound Zn transporters of the ZIP and
ZnT families.
3,8 Another important checkpoint in the Zn
homeostatic system appears to be the blood plasma. About 75%
of total Zn (15−20 μM
9) is bound to serum albumin,
10 the
most abundant plasma protein (ca. 600 μM),
11 which contains
585 amino acids arranged into three homologous domains
(Figure 1). One of its major functions is the transport and
delivery of fatty acids, which otherwise are only sparingly
soluble in aqueous solution. Crystallographic studies have
identified five major and up to five additional low-affinity
binding sites for fatty acids with different chain lengths.
12
Importantly, rather than being an indiscriminate sponge for a
variety of molecules, albumin is a biologically active protein
with regulatory functions for many cell types.
13
Our investigation was based on the recent structural
characterization of the major Zn binding site A on human
serum albumin (HSA; Figures 2A and 4B).
14 This site bridges
the domain I and II interface and is formed by His67 and
Asn99 in domain I and His247 and Asp249 in domain II. X-ray
crystal structures of HSA revealed that the site is disrupted in all
fatty-acid-bound structures [Figure 2A and Figure S1 in the
Supporting Information (SI)] as a result of a large conforma-
tional change induced by fatty acid binding to site FA2. This
site is composed of two half-sites, one in each of domains I and
II. A fatty acid in this site acts like a pin that fixes the two
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Figure 1. Domain structure of albumin and fatty acid binding sites.
Overlaid structures with PDB codes: 1bj5, HSA with five myristates,
pink (the protein backbone is also shown); 1e7e, HSA with 10
decanoates, green; 1gnj, HSA with seven arachidonates, light-yellow.
12
FA1−5, major sites; fa6−10, minor sites.
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fatty-acid-free conformation.
12 The physiological relevance of
this dramatic conformational change has remained enigmatic.
We hypothesized that simultaneous zinc binding to site A
and fatty acid binding to site FA2 may be incompatible.
14 This
was supported by the observation that high concentrations of
either natural fatty acids or octanoate (OCT; C8) lead to the
perturbation of a peak corresponding to site A in 111Cd or
113Cd NMR spectra (Figure S2).
14,15 However, it has not been
demonstrated experimentally whether Zn2+, the actual physio-
logical binding partner, hampers fatty acid binding to albumin
or vice versa. Neither Zn2+ nor fatty acids possess readily
exploitable spectroscopic features, but 1H NMR spectroscopy
has previously been used to study protonation equilibria,
conformational changes, and Zn2+ binding via monitoring of
histidine Hε1 resonances.
14,16 We used this method to explore
the effects of OCT on Zn2+ binding to albumin.
Addition of OCT to HSA (Figure 2B and Figure S3) had a
strong effect on several resonances, including those of the two
Zn-binding His residues (peaks 1 and 4
14), consistent with a
significant influence of fatty acid binding on the environment of
these residues and with the perturbation of peak A in 111Cd
NMR spectra. However, peak 4 was absent in the presence of
both Zn2+ and OCT, just as in the presence of Zn2+ alone. This
suggests that the presence of OCT does not abolish Zn binding
to site A, despite its clear effect on 111Cd binding. Thus,
although 1H NMR allowed these separate binding events to be
monitored and confirmed the participation of His67 and
His247 in both cases, it could not resolve whether Zn binding is
thermodynamically favored over OCT binding or whether
simultaneous binding of OCT to FA2 and Zn2+ to site A is
possible.
To address this, we developed an isothermal titration
calorimetry (ITC) approach to study competitive binding.
ITC is universally applicable to equilibrium reactions, as it
measures thermal effects arising from molecular interactions,
and it has been used successfully for the determination of
metal−protein stability constants,
17 including those of Cu, Ni,
and Co with albumin.
18 Interactions between proteins and fatty
acids have also been studied by microcalorimetry,
19 but no
calorimetric studies of competitive metal/fatty acid binding to a
protein have been reported.
First, binding to bovine serum albumin (BSA) in Tris-
buffered solutions at pH 7.2 was studied. BSA was chosen
because of the high sample consumption of ITC; notably,
however, the sequences of BSA and HSA are 75% identical, and
their binding properties for Zn and fatty acids are very
similar.
11,20,21 The reaction of Zn2+ with BSA under these
conditions was exothermic (Figure S4), and in agreement with
literature findings,
20,21 more than 1 molar equiv of Zn2+ could
bind to BSA. Under the experimental conditions, two binding
constants were captured (Figure 3A). Previous equilibrium
dialysis studies suggested the presence of a third Zn binding
site,
21 but it was too weak to be detected at the albumin
concentration employed. Evaluation of the data using a model
with two sequential binding constants yielded a conditional
stability constant, log KZnBSA′ = 5.67, for the first equivalent of
Zn2+. Correction for the effects of pH and Tris concentration
(see the SI) gave log K = 7.0 ± 0.3 for the stoichiometric
constant, in reasonable agreement with literature values.
20,21
ITC was also applied to study fatty acid binding to albumin.
Several data sets for OCT binding at various albumin
concentrations (25, 50, and 500 μM) were acquired (Figure
3B and Figures S5 and S6). Fitting models employing two sets
of binding sites gave log K = 5.4 ± 0.4 for the highest-affinity
class and log K = 3.3 ± 0.4 for the other set of sites. Previous
studies of OCT binding reported values between 6.3 (Scatchard
plots from rate-of-dialysis measurements)
22 and 4.53 (stepwise
constants from equilibrium dialysis measurements)
23 for the
highest-affinity site.
After it had been established that ITC yields thermodynamic
data consistent with literature values for the binary systems, the
ternary system was studied to investigate whether Zn2+ and
OCT binding to BSA are interactive. The results of titrations
with Zn2+ in the presence of 5 molar equiv of OCT (to ensure
that FA2 was populated) were indistinguishable from those in
the absence of fatty acid (Figure 3A). Conversely, the presence
of 1 molar equiv of Zn2+ did not significantly affect the affinity
Figure 2. Binding events at the domain I/II interface affect several His
Hε1 resonances. (A) Interface with the disrupted Zn-binding site A
(magenta) and interdomain His residues likely to be affected by fatty
acid binding in site FA2. The 11 resolved carbons of Myr2 in PDB
entry 1bj5 are shown as pink spheres. (B) Effects of 1 molar equiv of
Zn and 5 molar equiv of OCT on His Hε1 resonances. Peaks 1 and 4
are assigned to His67 and His247;
14 full titration data are shown in
Figure S3.
Figure 3. Competitive binding of Zn and OCT to BSA studied by
ITC. (A) Zn binding to BSA (25 μM) in the presence and absence of
5 molar equiv of OCT. (B) OCT binding to BSA and Zn1BSA. Open
circles with blue fits correspond to binary systems and filled circles
with red fits to ternary systems. In each case, 34 injections of 8 μLo f
333 μM ligand (Zn or OCT) were delivered over 16 s with 240 s
between injections for complete equilibration.
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concentrations studied (Figure 3B and Figure S6).
Thus, the 1H NMR data for the ternary system likely reflect
simultaneous binding of Zn and OCT. Bhattacharya et al.
12b
reported that HSA in the presence of OCT does not crystallize
in a form that is isomorphous with all other fatty-acid-
containing X-ray crystal structures, and they speculated that at
least 10 carbon atoms may be needed to elicit the fatty-acid-
induced conformational change. Our molecular model in which
both Zn and OCT are bound simultaneously (Figure 4B)
shows that a C8 chain can indeed be accommodated in a
truncated FA2 site without the conformational change observed
upon binding of longer-chain fatty acids.
To address the suspected impact of chain length, we
conducted further competition experiments using the C14
fatty acid myristate (MYR). The binding of MYR to albumin
(Figure S7) closely matches that of the physiologically most
abundant palmitate and stearate in terms of binding sites
12 but
is slightly weaker.
23 Titrations with Zn2+ in the presence of
increasing amounts of MYR (Figure 5A) revealed that the
stoichiometry (Figure 5B) and/or affinity of Zn2+ decrease
dramatically in the presence of >1 molar equiv of MYR.
Conversely, MYR titrations of the 1:1 Zn:BSA complex showed
that the energetics but not the stoichiometry of the binding
reaction are affected by Zn2+, as indicated by a decrease in
affinity and exothermicity (Figure 5C; ΔΔH = 1.1 kcal/mol,
average for five Myr). These observations can be rationalized by
assuming that the binding of MYR requires the dissociation of
Zn2+ from BSA; since the binding reaction is exothermic (ΔH =
−4.7 kcal/mol), this dissociation must be endothermic,
although the difference in experimental conditions precludes
direct quantitative comparisons.
Besides highlighting the complexity of a system with two or
three binding sites for one ligand and 5−10 binding sites for
another, these experiments unequivocally confirm the hypoth-
esis that binding of long-chain fatty acids to albumin and Zn2+
is interactive. They also indicate that the affinity of MYR is
higher than that of Zn2+ and suggest that elevated levels of
physiological fatty acids have a striking effect on Zn binding to
albumin. Inhibition of the binding to HSA of a thiosemicarba-
zonato complex of Cu2+ by stearate was reported,
24 but no
molecular explanation was given. Unexpectedly, a second Zn-
binding site was also affected by MYR (Figure 5A). The
location of this site is unknown, but a likely candidate is Cd site
B. Indeed, addition of 5 molar equiv of MYR to Cd2BSA
perturbed both peak A and peak B (Figure 5D). An effect of
fatty acids on site B has not been reported previously.
Our observations raise new questions regarding plasma Zn
distribution and its dependence on fatty acid levels and stress
the need to identify site B. Under normal physiological
conditions, 0.1−2 fatty acid molecules are bound to albumin.
The allosteric switch we have studied may play a so-far
overlooked role in fatty-acid-mediated Zn fluxes and explain
marked shifts in the systemic Zn distribution
2−5 under a variety
of conditions that are also characterized by high plasma levels
of fatty acids,
11,25−27 such as fasting, exercise, and pathological
Figure 4. Different binding modes for (A) medium- and (B) short-
chain fatty acids in site FA2 on HSA. Fatty acid molecules are shown
in pink. The colored surfaces represent Analytical Connolly surfaces of
the residues forming the binding pocket. In both models, the
carboxylate headgroup interacts with R257, and the hydrophobic half-
pocket in domain II (blue) is formed by residues L250, L251, A254,
A258, L283, and L284. (A) HSA with bound MYR, based on PDB
entry 1bj5. Three C atoms have been added to the C11 chain resolved
in the X-ray structure. Domain I (orange and yellow) contributes to
the fatty acid binding site an extended half-pocket comprising residues
R10, L14, F19, L22, V23, A26, L66, and Y150. The complete pocket
can be formed only if the zinc site (labeled residues) is disrupted. (B)
HSA with OCT and Zn2+ (purple) bound simultaneously. OCT is
short enough to be accommodated predominantly in the domain II
pocket. Hydrophobic residues L14, F19, L22, and L155 form a new
half-pocket without disrupting the zinc site.
Figure 5. Competitive binding of metals and MYR to BSA. (A) Effect
of increasing amounts of MYR on the zinc-binding capacity of BSA.
ITC curves for titrations of 333 μMZ n 2+ into 25 μM BSA in the
presence and absence of varying amounts (0−5 molar equiv) of MYR
in 50 mM Tris/50 mM NaCl (pH 7.2). The fits (Figure S8) allowed
estimates of the ratio of site A availability, as shown in (B). A clear
downward trend was observed. A 4:1 MYR:Zn molar ratio suppressed
occupation of site A almost completely. A second binding site was also
affected by fatty acid binding (see D). (C) ITC curves for titrations of
500 μM MYR into 12.5 μM BSA or Zn1BSA. These titrations were
carried out in H2O because of the insufficient solubility of MYR in Tris
buffer. The fits (Figure S9) correspond to a model with one set of
binding sites to estimate the stoichiometry for the highest-affinity sites.
This equaled 5.0 ± 0.3, and the average log K was 6.3 ± 0.4 in the
absence and 5.9 ± 0.4 in the presence of Zn2+. More complex fits were
possible, but the data were insufficient to justify them. (D) 111Cd
NMR spectra of Cd2BSA recorded in the absence and presence of 5
molar equiv of MYR. Peaks A and B were both suppressed by MYR.
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28 diabetes, and liver or cardiovascular
disease, including atherosclerosis
28 and myocardial infarction.
29
Besides the major effects expected at abnormally high levels of
fatty acids, however, possibly the most important outcome of
this study is the fact that we observed a measurable effect even
with just 1 or 2 molar equiv of fatty acid (i.e., normal
physiological levels). This is consistent with conclusions by
Simard et al.,
26 who identified FA2 as one of the three high-
affinity sites on HSA. Importantly, the 13CN M Rp e a k
corresponding to palmitate bound to FA2 began to emerge
even at a ratio of 1:1.
27 This suggests that the affinities of FA
sites 4 and 5 (known high-affinity sites) and 2 are very similar
and that FA2 is indeed populated to a considerable extent even
at normal physiological fatty acid levels. Together with the
present study, this means that fatty acids at all concentrations
have an impact on the distribution of Zn2+ in plasma.
The direct consequences of Zn displacement from albumin
are unknown, but because Zn is both a signaling agent and
potentially toxic to cells,
14,30 significant effects can be expected
even if just a fraction of plasma Zn becomes mobilized by
subtle changes in plasma fatty acids. This molecular link
between energy metabolism and Zn speciation may prove to be
of clinical significance. Among the wide range of metabolic
processes affected by zinc,
1 we highlight documented plasma
zinc effects on cytokine biology
31 and hemostasis,
32 including
blood coagulation. This may be mediated by the Zn-dependent
interaction between histidine-rich glycoprotein and the
anticoagulants heparin and heparan sulfate.
33
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Biol. 2000, 303, 721. (c) Petitpas, I.; Grüne, T.; Bhattacharya, A. A.;
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